Viral Rebound Uncommon After Molnupiravir, Nirmatrelvir-Ritonavir Therapy

FRIDAY, Dec. 9, 2022 -- Patients with COVID-19 taking molnupiravir or nirmatrelvir-ritonavir rarely have viral rebound, and rebound is not associated with increased mortality risk, according to a study published online Dec. 6 in JAMA Network...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news